Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice

Biochimie

Volumn 115, Issue , 2015, Pages 86-92

  Wu, Wei Bin ^a,b   Chen, Yuan Yuan ^c   Zhu, Bo ^a   Peng, Xiao Min ^a   Zhang, Song Wen ^a   Zhou, Mei Ling ^d  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Alcoholic liver disease; Alcoholic steatohepatitis; Farnesoid X receptor; Lieber DeCarli ethanol diet

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; BILE ACID; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; CYTOCHROME P450 2E1; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; COLLAGEN; FARNESOID X-ACTIVATED RECEPTOR;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC STEATOHEPATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; BIOACCUMULATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME MECHANISM; FATTY LIVER; FEEDING; HEPATITIS; HISTOPATHOLOGY; LIPID LIVER LEVEL; LIQUID; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; WILD TYPE; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; FATTY LIVER, ALCOHOLIC; GENE INACTIVATION; GENETICS; INJURIES; LIVER; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; BILE ACIDS AND SALTS; COLLAGEN; DISEASE PROGRESSION; ETHANOL; FATTY LIVER, ALCOHOLIC; GENE KNOCKOUT TECHNIQUES; LIVER; MICE; MICE, INBRED C57BL; NF-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84930626486     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2015.05.014     Document Type: Article

References (43)

1. B. Gao, and R. Bataller Alcoholic liver disease: pathogenesis and new therapeutic targets Gastroenterology 141 2011 1572 1585
2. J. Altamirano, and R. Bataller Alcoholic liver disease: pathogenesis and new targets for therapy Nat. Rev. Gastroenterol. Hepatol. 8 2011 491 501
3. R.S. O'Shea, S. Dasarathy, A.J. McCullough Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G Alcoholic liver disease Hepatology 51 2010 307 328
4. M.R. Lucey, P. Mathurin, and T.R. Morgan Alcoholic hepatitis N. Engl. J. Med. 360 2009 2758 2769
5. B.M. Forman, E. Goode, J. Chen, A.E. Oro, and D.J. Bradley Identification of a nuclear receptor that is activated by farnesol metabolites Cell 81 1995 687 693
6. W. Seol, H.S. Choi, and D.D. Moore Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors Mol. Endocrinol. 9 1995 72 85
7. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, and G. Lambert Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
8. T.T. Lu, M. Makishima, J.J. Repa, K. Schoonjans, and T.A. Kerr Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors Mol. Cell. 6 2000 507 515
9. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, and D.D. McKee A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol. Cell. 6 2000 517 526
10. S. Zhang, J. Wang, Q. Liu, and D.C. Harnish Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis J. Hepatol. 51 2009 380 388
11. Y.D. Wang, W.D. Chen, M. Wang, D. Yu, and B.M. Forman Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response Hepatology 48 2008 1632 1643
12. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C. Willemsen, and W. Renooij Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 60 2011 463 472
13. W. Wu, B. Zhu, X. Peng, M. Zhou, and D. Jia Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease Biochem. Biophys. Res. Commun. 443 2014 68 73
14. S. Liu, T.H. Yeh, V.P. Singh, S. Shiva, and L. Krauland beta-catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice Hepatology 55 2012 931 940
15. Y. Lu, J. Zhuge, X. Wang, J. Bai, and A.I. Cederbaum Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice Hepatology 47 2008 1483 1494
16. W. Wu, X. Liu, X. Peng, R. Xue, and L. Ji Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis Biochem. Biophys. Res. Commun. 448 2014 50 55
17. Y. Najima, N. Yahagi, Y. Takeuchi, T. Matsuzaka, and M. Sekiya High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding J. Biol. Chem. 280 2005 27523 27532
18. L. Romics Jr., K. Kodys, A. Dolganiuc, L. Graham, and A. Velayudham Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver Hepatology 40 2004 376 385
19. H.J. Wang, B. Gao, S. Zakhari, and L.E. Nagy Inflammation in alcoholic liver disease Annu Rev. Nutr. 32 2012 343 368
20. J. Petrasek, S. Bala, T. Csak, D. Lippai, and K. Kodys IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice J. Clin. Invest 122 2012 3476 3489
21. P. Mandrekar, A. Ambade, A. Lim, G. Szabo, and D. Catalano An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice Hepatology 54 2011 2185 2197
22. M. Yin, M.D. Wheeler, H. Kono, B.U. Bradford, and R.M. Gallucci Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice Gastroenterology 117 1999 942 952
23. M. Muhlbauer, B. Allard, A.K. Bosserhoff, S. Kiessling, and H. Herfarth Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells Am. J. Physiol. Gastrointest. Liver Physiol. 286 2004 G1000 G1008
24. A.M. Elsharkawy, and D.A. Mann Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis Hepatology 46 2007 590 597
25. T. Luedde, and R.F. Schwabe NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 8 2011 108 118
26. M.A. Collart, P. Baeuerle, and P. Vassalli Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B Mol. Cell. Biol. 10 1990 1498 1506
27. A. Ishikado, Y. Nishio, K. Yamane, A. Mukose, and K. Morino Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells Atherosclerosis 205 2009 404 412
28. M.G. Roma, F.D. Toledo, A.C. Boaglio, C.L. Basiglio, and F.A. Crocenzi Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications Clin. Sci. (Lond) 121 2011 523 544
29. F.Y. Lee, H. Lee, M.L. Hubbert, P.A. Edwards, and Y. Zhang FXR, a multipurpose nuclear receptor Trends Biochem. Sci. 31 2006 572 580
30. I. Koutsounas, C. Giaginis, and S. Theocharis Farnesoid X receptor (FXR) from normal to malignant state Histol. Histopathol. 27 2012 835 853
31. B.Y. Tung, and R.L. Carithers Jr. Cholestasis and alcoholic liver disease Clin. Liver Dis. 3 1999 585 601
32. G. Paumgartner, and U. Beuers Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 2002 525 531
33. J.C. Trinchet, M.F. Gerhardt, B. Balkau, C. Munz, and R.E. Poupon Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features J. Hepatol. 21 1994 235 240
34. L. Spahr, L. Rubbia-Brandt, M. Genevay, A. Hadengue, and E. Giostra Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis BMC Gastroenterol. 11 2011 115
35. S.C. Glover, J.L. McPhie, and P.W. Brunt Cholestasis in acute alcoholic liver disease Lancet 2 1977 1305 1307
36. F. Lian, X. Xing, G. Yuan, C. Schafer, and S. Rauser Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage Biochem. J. 438 2011 315 323
37. K. Allen, H. Jaeschke, and B.L. Copple Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis Am. J. Pathol. 178 2011 175 186
38. G. Svegliati-Baroni, F. Ridolfi, R. Hannivoort, S. Saccomanno, and M. Homan Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor Gastroenterology 128 2005 1042 1055
39. G. Pelletier, D. Roulot, T. Davion, C. Masliah, and X. Causse A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice Hepatology 37 2003 887 892
40. V. Gurung, P. Middleton, S.J. Milan, W. Hague, and J.G. Thornton Interventions for treating cholestasis in pregnancy Cochrane Database Syst. Rev. 6 2013 CD000493
41. T. Miura, R. Ouchida, N. Yoshikawa, K. Okamoto, and Y. Makino Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid J. Biol. Chem. 276 2001 47371 47378
42. I. Kessova, and A.I. Cederbaum CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury Curr. Mol. Med. 3 2003 509 518
43. A. Butura, K. Nilsson, K. Morgan, T.R. Morgan, and S.W. French The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model J. Hepatol. 50 2009 572 583